Author

Adrienne D. Briggs

Observed name: Adrienne Briggs

Institution: HonorHealth

Observed institutions: Louisiana State University, Cedars-Sinai Medical Center, University of Arizona, University of California, Los Angeles, Louisiana State University in Shreveport, HonorHealth, Arizona Oncology, Columbus Community Clinical Oncology Program, University of Arizona Cancer Center, UCLA Jonsson Comprehensive Cancer Center, University of Arkansas for Medical Sciences

OpenAlex ID: A5103710102

Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients

2002 · James R. Berenson, John J. Crowley, et al. · Blood · 240

Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3

2024 · Mark J. Levis, Mehdi Hamadani, et al. · Journal of Clinical Oncology · 225

Post-Transplant Cyclophosphamide–Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors

2024 · Brian C. Shaffer, Mahasweta Gooptu, et al. · Journal of Clinical Oncology · 109

Bone Marrow Transplantation for Non-Hodgkin's Lymphoma: A Review

1997 · Donna E. Salzman, Adrienne D. Briggs, et al. · The American Journal of the Medical Sciences · 11

Post-Transplant Cyclophosphamide Eliminates Disparity in GvHD-Free, Relapse-Free Survival and Overall Survival between 8/8 Matched and 7/8 Mismatched Unrelated Donor Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies

2023 · Jeffery J. Auletta, Monzr M. Al Malki, et al. · Blood · 9

Post-Transplant Cyclophosphamide Eliminates Disparity in GvHD-Free, Relapse-Free Survival and Overall Survival between 8/8 Matched and 7/8 Mismatched Unrelated Donor Hematopoietic Cell Transplantation in Adults with Acute Leukemia or MDS

2024 · Jeffery J. Auletta, Monzr M. Al Malki, et al. · Transplantation and Cellular Therapy · 6

No Differences in Stem Cell Transplantation Utilization Rates (STUR) by Ethnicity after Referral to a Transplant Center for Multiple Myeloma (MM): Implications for Improving Stur Rates in Minorities

2017 · Jeffrey Schriber, Chris Bean, et al. · Transplantation and Cellular Therapy · 3

MODULAATE, A 2-Part, Dose-Finding, Efficacy and Safety Trial with Alpha-1 Antitrypsin (AAT) for Prevention of Acute Graft vs. Host Disease (aGVHD): Part 1 Safety and Pharmacokinetic (PK) Results

2022 · John Mallee, Mitchell E. Horwitz, et al. · Transplantation and Cellular Therapy

PBSCT without the Use of Growth Factors Post Transplant: Cost Savings without Clinical Consequences. Is It Time for a Change in Standard Practice?

2016 · Jeffrey Schriber, Eileen Simpson, et al. · Transplantation and Cellular Therapy

Post Transplant Cytoxan in Patients over the Age of 60 Undergoing Allogeneic Transplant: Less Graft Versus Host Disease (GVHD) Related Deaths Than in Patients Treated with Standard Tacrolimus Methotrexate

2016 · Jeffrey Schriber, Veena Fauble, et al. · Transplantation and Cellular Therapy

Single Dose Plerixafor and Multi-Day Apheresis: Skip Dosing Enables Cost Efficient Mobilization for Patients Close to Achieving Treatment Goals

2015 · Jeffrey Schriber, Andrew Szetela, et al. · Transplantation and Cellular Therapy

Autologous Stem Cell Transplantation For Multiple Myeloma In Patients Over Age 70: Decision Making, Eligibility, and Preliminary Outcomes

2013 · Aleksandra E Schriber, Gail Sulski, et al. · Blood

Transplant: The Ultimate Team Sport. A Potential Answer to Workforce Challenges in Hematopoietic Stem Cell Transplant

2013 · Jeffrey Schriber, Virginia G. Piper, et al. · Transplantation and Cellular Therapy

Works count: 14

Citation count: 602

H-index: 6

I10-index: 4